Abacavir

Generic Name
Abacavir
Brand Names
Epzicom, Kivexa, Triumeq, Trizivir, Ziagen
Drug Type
Small Molecule
Chemical Formula
C14H18N6O
CAS Number
136470-78-5
Unique Ingredient Identifier
WR2TIP26VS
Background

Abacavir (ABC) is a powerful nucleoside analog reverse transcriptase inhibitor (NRTI) used to treat HIV and AIDS. Chemically, it is a synthetic carbocyclic nucleoside and is the enantiomer with 1S, 4R absolute configuration on the cyclopentene ring. In vivo, abacavir sulfate dissociates to its free base, abacavir.

Indication

Abacavir is indicated in combination with other anti-retroviral agents for the treatment of HIV-1 infection. It is available in a combination product alongside dolutegravir and lamivudine for the treatment of adult and pediatric patients with HIV-1 who weigh ≥10 kg.

Associated Conditions
Human Immunodeficiency Virus Type 1 (HIV-1) Infection
Associated Therapies
-

Once-Daily Drug Regimen for HIV-Infected Patients

First Posted Date
2002-12-10
Last Posted Date
2008-03-04
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
25
Registration Number
NCT00001968
Locations
🇺🇸

National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, Maryland, United States

A HIV Study Of A Fixed-Dose Combination Tablet In Antiretroviral Experienced Patients

First Posted Date
2002-09-23
Last Posted Date
2020-03-24
Lead Sponsor
ViiV Healthcare
Target Recruit Count
240
Registration Number
NCT00046176
Locations
🇵🇷

GSK Investigational Site, Rio Piedras, Puerto Rico

New Tablet Containing Two FDA Approved Anti-HIV Drugs For Antiretroviral Therapy Experienced HIV-1 Infected Subjects

First Posted Date
2002-09-04
Last Posted Date
2020-03-24
Lead Sponsor
ViiV Healthcare
Target Recruit Count
166
Registration Number
NCT00044577
Locations
🇬🇧

GSK Investigational Site, London, United Kingdom

Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy

First Posted Date
2002-08-01
Last Posted Date
2022-07-22
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
1578
Registration Number
NCT00042289
Locations
🇺🇸

Usc La Nichd Crs, Los Angeles, California, United States

🇿🇦

Wits RHI Shandukani Research Centre CRS, Johannesburg, Gauteng, South Africa

🇺🇸

Boston Medical Center Ped. HIV Program NICHD CRS, Boston, Massachusetts, United States

and more 59 locations

Continued Antiretroviral Therapy With Abacavir, Amprenavir and Efavirenz

Phase 2
Completed
Conditions
First Posted Date
1999-11-04
Last Posted Date
2008-03-04
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
25
Registration Number
NCT00001758
Locations
🇺🇸

National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, Maryland, United States

© Copyright 2024. All Rights Reserved by MedPath